ArticleJournal of Taibah University Medical Sciences2026
Impact of SLCO1B3 767G>C (rs60140950) polymorphism on paclitaxel response in Iraqi women with breast cancer.
Article in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aims of this study were to identify genetic polymorphism in solute carrier organic anion transporter 1B3 (SLCO1B3 767G>C (rs60140950)), and to examine the impacts of this polymorphism on the efficacy and safety of paclitaxel in Iraqi women with breast cancer (BC). Methods: This cross-sectional observational study involved 150 women with BC who were administered paclitaxel. During the second week of paclitaxel therapy, these women were evaluated individually using a questionnaire to gather demographic information, such as their age and body mass index, as well as the likelihood and intensity of adverse effects of paclitaxel. Neutropenia levels and BC biomarkers were also evaluated. Result: The wild-type genotype of the SLCO1B3 767G>C genetic polymorphism was identified in approximately 76% of BC cases. The mutant type (CC) and heterozygous type (GC) were identified in approximately 10% and 14% of cases, respectively. Among Iraqi women with BC carrying GG, GC, and CC genotypes, no significant differences were found in BC markers (cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA)) or paclitaxel-related side effects (neutropenia, oral mucositis, and peripheral neuropathy) at Conclusion: The distribution of the SLCO1B3 767G>C (rs60140950) genotype was high among Iraqi women with BC. No significant correlations were found between the SLCO1B3 767G>C genetic variant and changes in BC markers (CA 15-3 and CEA) or the incidence of early paclitaxel-related adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.